Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?
Elizabeth Miller
;
(2022)
Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?
EBioMedicine, 79.
104034-.
ISSN 2352-3964
DOI: 10.1016/j.ebiom.2022.104034
Identifying an immunological correlate of protection (CoP) is a key objective in vaccine development allowing licensure of new vaccines without direct evidence of efficacy. Having a CoP for COVID-19 vaccines is particularly important as establishing efficacy for new vaccine platforms in placebo-controlled trials is becoming ethically problematic with the growing availability of first generation vaccines with proven efficacy.
Item Type | Article |
---|---|
Elements ID | 176906 |
ORCID: https://orcid.org/0000-0002-1884-0097